Soligenix Inc — Quarterly Cash Flow (NASDAQ:SNGX)

Financials

Total assets 8.97 M7.75 M5.76 M11.29 M9.24 M Total liabilities 4.85 M4.13 M3.93 M3.7 M3.94 M Total equity 4.12 M3.61 M1.83 M7.6 M5.29 M Total liabilities & shareholders' equities 8.97 M7.75 M5.76 M11.29 M9.24 M Total debt 111.86 K———— Net debt 111.86 K————

뉴스

솔리제닉스, 베체트병 치료제 영국 규제 당국 지정 획득

Soligenix receives UK regulatory designation for Behçet’s drug

솔리제닉스, 희귀 의약품 지정에 대한 EMA 긍정적 의견 접수

Soligenix receives positive EMA opinion for orphan drug status

솔리제닉스, 베체트병 치료 데이터 호조에 주가 상승

Soligenix stock rises after positive Behçet’s Disease treatment data

솔리제닉스, 베체트병 치료제 SGX945 임상 긍정적 결과 발표

Soligenix reports positive results from SGX945 trial for Behçet’s disease

Soligenix Psoriasis Trial Extension Shows Better Outcomes With New Gel - Soligenix (NASDAQ:SNGX)

솔리제닉스, 건선 겔 치료제 긍정적 결과 발표

Soligenix reports positive results from psoriasis gel treatment trial

First patient dosed in Synairgen’s global phase 2 INVENT study